Company: NCNA
Filing Date: 2025-04-29
Form Type: F-1/A
Source: 0001193125-25-103135
Chunk: 34

Company: NuCana plc
Filing Date: 2025-04-29
Form: F-1/A
Chunk 34
---
10 increase in the assumed combined public offering price of $0.5601 per ADS and the accompanying Series A Warrant and Series B Warrant would increase the as adjusted net tangible book value per ADS by 18

$1.1 million and increase the dilution per ADS to investors participating in this offering by $0.04 (assuming no sale of Pre-FundedWarrants in this offering), after deducting Placement Agent fees and estimated offering expenses payable by us and excluding the proceeds, if any, from the exercise of the Warrants issued in this offering. A $0.10 decrease in the assumed combined public offering price per ADS and the accompanying Series A Warrant and Series B Warrant would decrease the as adjusted net tangible book value per ADS by $1.1 million and decrease the dilution per ADS to investors participating in this offering by $0.04 (assuming no sale of Pre-FundedWarrants in this offering), after deducting Placement Agent fees and estimated offering expenses payable by us and excluding the proceeds, if any, from the exercise of the Warrants issued in this offering. The share information above excludes:

| • |     | 17,175,304 ordinary shares issuable upon exercise of outstanding options under our equity compensation plans as 
 of December 31, 2024 at a weighted average exercise price of £2.11 per ordinary share; and                      |

| • |     | 29,123 ordinary shares issued upon exercise of options under our equity incentive plans subsequent to December 
 31, 2024 at an exercise price of £0.04 per ordinary share.                                                     |

To the extent these outstanding options or any newly issued options are exercised, or we issue additional securities in the future, there will be further dilution to the new investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our shareholders and ADS holders. 19

DESCRIPTION OF SHARE CAPITAL

The following describes our issued share capital, summarizes the material provisions of our articles of association and highlights certain differences in corporate law in the United Kingdom and the United States. Please note that this summary is not intended to be exhaustive. For further information please refer to the full version of our articles of association, which is included as an exhibit to the registration statement